This is a working overview of GHRH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
butyl The alkyl functional group derived from either of the two isomers of butane, with the generic chemical formula –C4H9. It may occur as a substituent in organic compounds or exist independently as an ion or radical. In IUPAC nomenclature, the presence of a butyl substituent is indicated with the prefix butyl in the name of the compound, or with the abbreviation Bu in chemical formulae; e.g. butyl alcohol (butanol), which may occur in any of five different isomeric forms depending on the arrangement of the four carbon atoms, is often written with the generic formula CH4CH9OH or BuOH.
== Cell cycle regulation == The eukaryotic cell cycle is regulated through the synthesis, degradation, binding interactions, post-translational modifications of regulatory proteins. Of these regulatory proteins, two ubiquitin ligases are crucial for progression through cell cycle checkpoints. The anaphase-promoting complex (APC) controls the metaphase-anaphase transition, while the SCF complex controls G1/S and G2/M transitions. Specifically, SCF has been shown to regulate centriole splitting from late telophase to the G1/S transition. SCF activity is largely regulated by post-translational modifications. For instance, ubiquitin-mediated autocatalytic degradation of FBPs is a mechanism of decreasing SCF activity. Well-characterized cell cycle substrates of SCF complexes include:
There are several strategies for removal and/or negation of ion suppression. These approaches may require in-depth understanding of the ionisation mechanisms involved in different ionisation sources or may be completely independent of the physical factors involved.
=== Exercise === While many environmental factors may exacerbate Parkinson's disease, exercise is considered to be one of the main protective factors for neurodegenerative disorders, including Parkinson's disease. The use of exercise can reduce risk or delay development of PD (primary prevention). Higher levels of moderate to vigorous physical activity are associated with a lowered risk of PD. There are also indications that exercise may slow or halt PD progression (secondary prevention). For example, increased levels of physical activity have been associated with slower deterioration on measures of daily living activities. This was found regardless of people's initial physical activity levels. Finally, exercise may help to reduce some symptoms of PD (tertiary prevention). Underlying protective mechanisms are not yet understood. Types of exercise that have been studied include aerobic exercise, resistance exercise, and balance and gait exercises. Respectively, they improve aerobic capacity, muscle strength, and postural stability/balance. Aerobic exercise includes physical activity that increases the heart rate. Resistance training uses tools like weights, bands, or bodyweight to challenge muscles, increasing strength and function over time. Goal-based exercises are often developed with the guidance of a physical therapist to target specific outcomes such as balance and gait.
Sources: en.wikipedia.org
== Applicable fiber types == There are many fiber types that can be excellent candidates for the preparation of preimpregnated fibers. The most common fibers among these candidates are the following fibers.
Black kōji produces citric acid during fermentation, which inhibits the growth of unwanted microorganisms. It is typically used for the production of awamori. There are three Aspergillus species that are used as black kōji:
A study highlight the importance of extending healthspans, not just lifespans and especially as life expectancy rises and demographics shift. Biological aging or the healthspan-lifespan gap (LHG) comes with a great cost burden to society, including potentially rising health care costs (also depending on types and costs of treatments). Scientists have noted that "[c]hronic diseases of aging are increasing and are inflicting untold costs on human quality of life". Further reasons to prioritize healthspans as much as lifespans include global quality of life or wellbeing. A scientific review concludes that accumulating data suggests dietary restriction (DR) – mainly intermittent fasting and caloric restriction – results in many of the same beneficial changes in adult humans as in studied organisms, potentially increasing health- and lifespan. A review published a few days later provides an overview of DR as an intervention and develops a framework for a proposed field of "precision nutrigeroscience". A study published a few days later identifies circadian-regulated autophagy as a critical contributor to intermittent time-restricted fasting-mediated lifespan extension in Drosophila and suggests that only certain forms of and/or combinations with intermittent fasting – intervals during which no food but only e.g. water and tea/coffee are ingested – may be effective beyond the benefits of healthy body weight. Scientists show that and how the flavonoid Procyanidin C1 of the antioxidant grape seed extract increases the health- and lifespan of mice.
Combination of small size, ease of engineering, high affinity and specificity makes Affibody molecules suitable alternative as monoclonal antibodies for both molecular imaging and therapeutical applications, especially for the receptor-overexpressing tumors. These proteins are characterized by a high rate of extravasation and rapid clearance of non-bound tracer from the circulation, as well as other nonspecific compartments, when compared to antibodies and their fragments
One-color light is well suited for traffic lights and signals, exit signs, emergency vehicle lighting, ships' navigation lights, and LED-based Christmas lights. Because of their long life, fast switching times, and visibility in broad daylight due to their high output and focus, LEDs have been used in automotive brake lights and turn signals. The use in brakes improves safety, due to a great reduction in the time needed to light fully, or faster rise time, about 200 milliseconds faster than an incandescent bulb. This gives drivers behind more time to react. In a dual intensity circuit (rear markers and brakes) if the LEDs are not pulsed at a fast enough frequency, they can create a phantom array, where ghost images of the LED appear if the eyes quickly scan across the array. White LED headlamps are beginning to appear. Using LEDs has styling advantages because LEDs can form much thinner lights than incandescent lamps with parabolic reflectors. Due to the relative cheapness of low output LEDs, they are also used in many temporary uses such as glowsticks and throwies. Artists have also used LEDs for LED art.
Sources: en.wikipedia.org
=== Inhibitors === Given the therapeutic potential of targeting ADAMTS7 in cardiovascular diseases, research has focused on developing selective small-molecule inhibitors. In 2024, the discovery of BAY-9835 was reported, representing the first potent, selective, and orally bioavailable inhibitor designed to target the catalytic domain of ADAMTS7. Concurrently, a series of novel hydroxamate-based arylsulfonamides were designed and synthesized to optimize selectivity starting from the non-selective lead compound EDV33; the optimized lead compound, a p-trifluoromethyl biphenyl sulfonamide, demonstrated nanomolar potency against ADAMTS7 and notable selectivity over ADAMTS5.
=== Honors === William H. Stein received numerous honors from Columbia University and the Albert Einstein College of Medicine of Yeshiva University, including: D.Sc. honoris causa, Columbia University (1973), D.Sc. honoris causa, Albert Einstein College of Medicine of Yeshiva University (1973), and the Award of Excellence Medal, Columbia University Graduate Faculty and Alumni Association (1973).
=== Unhappy marriage and divorce === Unhappily married couples suffer 3–25 times the risk of developing clinical depression, leading to divorce. Studies found that divorce and separation increases chances of an individual encountering depression, anxiety, substance abuse issues, insomnia, and financial hardship. Divorce and unhappy married couples not only affect the mental health of both the parents, but particularly the children of a separated home. Children of divorced parents engage in early sexual behavior, academic difficulties, substance abuse, depressive moods, and an increased chance of living in poverty due to family instability.
The regulation of food and dietary supplements by the Food and Drug Administration is governed by various statutes enacted by the United States Congress and interpreted by the FDA. Pursuant to the Federal Food, Drug, and Cosmetic Act and accompanying legislation, the FDA has authority to oversee the quality of substances sold as food in the United States, and to monitor claims made in the labeling of both the composition and the health benefits of foods. The FDA subdivides substances that it regulates as food into various categories—including foods, food additives, added substances (human-made substances that are not intentionally introduced into food, but nevertheless end up in it), and dietary supplements. Dietary supplements or dietary ingredients include vitamins, minerals, herbs, amino acids, and enzymes. Specific standards the FDA exercises differ from one category to the next. Furthermore, legislation had granted the FDA a variety of means to address violations of standards for a given substance category. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the FDA is responsible for ensuring that manufacturers and distributors of dietary supplements and dietary ingredients meet the current requirements. These manufacturers and distributors are not allowed to advertise their products in an adulterated way, and they are responsible for evaluating the safety and labeling of their product. The FDA has a "Dietary Supplement Ingredient Advisory List" that includes ingredients that sometimes appear on dietary supplements but need further evaluation.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.